Take your pick… there’s more than enough reasons to call this year historic.
While most are worth forgetting, looking back on the urgency and efficiency at which drugmakers around the world developed and distributed an approved COVID-19 is impressive. With all hands on deck, a process that usually takes up to 5-10 years was accomplished in about 10 months. Regardless of political motives or scientific skepticism, it’s hard to ignore the feat that managed to meet strict FDA guidelines.
And for the most part, Wall Street has responded to drugmakers with applause, as some of the biggest “epicenter” stocks have enjoyed quite the 2020 rally. Moderna (MRNA) has been the stock market standard as far as this new class of stocks, soaring more than 780% this year. Shares of Pfizer (PFE) sidekick BioNTech (BNTX) stock have enjoyed gains as high as 230% this year, while Johnson & Johnson (JNJ) has rallied 38% from March lows.
But with vaccines from Pfizer, BioNTech and Moderna rolling out as we speak, has the window closed on this unique opportunity for investors? According to MotleyFool.com, there are still two big names expected to come through in 2021, that look poised to continue their current rallies.
Novavax (NVAX) was awarded $1.6 billion this past summer by the Operation Warp Speed initiative and looks to build on its 3,000% stock gains next year, with the company expected to generate interim phase 3 trial data in the first quarter of 2021, before seeking FDA approval.
Likewise, Vaxart (VXRT) has seen shares soar at an impressive 2000% clip this year, which isn’t too far off from Novavax as far as the timeline of approval, but with one distinct advantage over many other drugmakers. Vaxart’s product is an orally administered tablet that’s stable at room temperature. In other words, it makes it easier to administer, transport, and store millions of doses.
Of course, much like any other drugmaker, the companies’ growth potential, as far as Wall Street is concerned, depends on late-stage trial results.